Pakistan to Launch Local Insulin Production with Russian Partnership

Local Insulin Manufacturing to Transform Diabetes Care

Pakistan is moving toward self-reliance in insulin production through a landmark partnership with Russia’s Zavod Medsintez and local firm Genetics Pharmaceuticals Private Limited. The collaboration involves an investment of nearly $80 million, aimed at reducing Pakistan’s dependence on imported insulin and strengthening its healthcare system.

The project will unfold in two phases. The first phase, worth $20 million, will establish an aseptic filling plant for insulin and related products. This facility will manage bulk imports and local filling operations, with completion expected by December 2028.

The second phase involves a $60 million investment in an Active Pharmaceutical Ingredient (API) production plant, enabling full-scale insulin manufacturing. This stage will include technology transfer and biotechnology development, ensuring Pakistan can produce insulin from API purification to final packaging. Completion is targeted for December 2031.

The Drug Regulatory Authority of Pakistan (DRAP) has already approved the marketing of Russian insulin products—Rosinsulin R, Rosinsulin C, and Rosinsulin M 30/70—in Pakistan. DRAP will closely monitor progress, requiring detailed stage-wise investment timelines to ensure compliance and transparency.

This initiative comes amid growing economic cooperation between Pakistan and Russia, with recent agreements also allowing Pakistani seafood exports to the Russian market. Analysts view the insulin project as a critical step in diversifying Pakistan’s pharmaceutical sector and addressing the rising burden of diabetes, which affects millions nationwide.

By investing in local production, Pakistan aims to reduce costs, improve accessibility, and secure long-term supply chains for essential medicines. Once operational, the facilities could also position Pakistan as a regional supplier of insulin and biotechnology products, boosting both healthcare resilience and economic growth.

This partnership represents a turning point in Pakistan’s healthcare landscape, promising to make diabetes treatment more affordable and accessible while reducing reliance on costly imports.